Susan Kozauer is a Psychiatry physician affiliated with Johnson & Johnson. OpenAlex indexes 28 publications with 276 citations (h-index 8); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7910 Woodmont Ave
Suite 1101
Bethesda, MD 208143002
Telephone
301-208-0930Registry record last updated 9 Jul 2007.
Clinical trials
- Clinical Trial Evaluating Lumateperone Monotherapy in the Treatment of Bipolar Depression or Major Depressive Disorder
Sponsor: Intra-Cellular Therapies, Inc.
- Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
Sponsor: Intra-Cellular Therapies, Inc.
- ITI-007 for the Treatment of Agitation in Patients With Dementia, Including Alzheimer's Disease
Sponsor: Intra-Cellular Therapies, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Research & Development, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Lumateperone for the Treatment of Major Depressive Disorder With Mixed Features or Bipolar Depression With Mixed Features
Journal of Clinical Psychopharmacology
2025 - Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder
The Journal of Clinical Psychiatry
2025 - Lumateperone monotherapy for major depressive episodes associated with bipolar disorder: efficacy and safety in a randomized placebo-controlled trial
International Clinical Psychopharmacology
2025 - LUMATEPERONE IN THE TREATMENT OF PATIENTS WITH MAJOR DEPRESSIVE DISORDER AND BIPOLAR DISORDER WITH ANXIOUS DISTRESS AND MIXED FEATURES
The International Journal of Neuropsychopharmacology
2025 - 610. LONG-TERM ADJUNCTIVE LUMATEPERONE TREATMENT IN MAJOR DEPRESSIVE DISORDER: RESULTS FROM A SIX-MONTH OPEN-LABEL EXTENSION STUDY
The International Journal of Neuropsychopharmacology
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Wayne Drevets, MD
Johnson & Johnson
Matthew Breyer, MD
Johnson & Johnson
Deepu Madduri, MD
Johnson & Johnson
Elliot Barnathan, MD
Johnson & Johnson
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”